Related Experiment Video
Updated: May 30, 2026

Inverse Probability of Treatment Weighting (Propensity Score) using the Military Health System Data Repository and National Death Index
Published on: January 8, 2020
Surrogates, meta-analysis and cost-effectiveness modelling: a combined analytic approach
Neil Hawkins1, Gerry Richardson, Alex J Sutton
1Centre for Health Economics, University of York, Heslington,York, UK. nsh2@york.ac.uk
Abstract:
Estimates of cost-effectiveness analyses are typically obtained either directly from 'trial' based analyses or indirectly via surrogate endpoints in 'model' based analyses. Data from clinical trials that include both surrogate and final endpoints can be used in a joint analysis that combines these two approaches. This joint approach allows the inclusion of information regarding the effects of treatment on surrogate endpoints while relaxing the strong assumption of 'conditional independence' associated with indirect model-based analyses. An example cost-effectiveness analysis of Chronic Disease Self-Management Programme is used to compare the different approaches. It is shown that despite using a common data set, the different analytic approaches produce differing estimates of the cost-effectiveness of the intervention and the value of future research. The paper concludes by discussing the selection of the appropriate analytic approach.
Related Concept Videos
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Actuarial Approach
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
Strategies for Assessing and Addressing Confounding
Confounding can be addressed at both the design phase of a study and through analytical methods after data...
Comparing the Survival Analysis of Two or More Groups